Our breast cancer findings suggest that c-MYC targeting represents a novel therapeutic axis distinct from BMP5/PTEN pathways, potentially offering unique advantages in hormone receptor-positive breast cancers where c-MYC dysregulation drives proliferative signaling. This evidence concerns the gene MYC and breast cancer.